Chalcogen Or Nitrogen Bonded Directly To The Imidazole Ring By Nonionic Bonding Patents (Class 514/398)
-
Publication number: 20140079791Abstract: The subject of the present invention is a transdermal preparation containing pharmaceutically active ingredient, wherein the particles of the active ingredient are coated with highly volatile silicones or a mixture thereof, and these coated particles are dispersed in a gel or cream base. The volatile silicone component is hexamethyldisiloxane and/or octamethyltrisiloxane and/or decamethylpentacyclo-siloxane. A further subject of the present invention is a method for the preparation of such pharmaceutical compositions.Type: ApplicationFiled: November 15, 2013Publication date: March 20, 2014Applicant: EGIS Pharmaceuticals Public Limited CompanyInventors: Endre Mikulásik, Patrik Fazekas
-
Patent number: 8673901Abstract: The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X1, R1, R2, R3, R4, and R5 are defined as set forth in the specification. The compounds are useful as potassium ion channel inhibitors.Type: GrantFiled: August 31, 2009Date of Patent: March 18, 2014Assignee: Xention LimitedInventors: Mushtaq Mulla, Derek Edward John, Richard John Hamlyn, Sasha Louise Garrett, Basil Hartzoulakis, David Madge, John Ford
-
Publication number: 20140066483Abstract: Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.Type: ApplicationFiled: November 4, 2013Publication date: March 6, 2014Applicant: Allergan, Inc.Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M.B. Luhrs
-
Patent number: 8664253Abstract: The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.Type: GrantFiled: February 22, 2010Date of Patent: March 4, 2014Assignee: Merck Sharp & Dohme CorpInventors: Ping Liu, Robert J. DeVita, Linus S. Lin, Marc D. Chioda, Terence G. Hamill, Wenping Li
-
Patent number: 8664254Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: November 26, 2012Date of Patent: March 4, 2014Assignee: Theravance, Inc.Inventors: Seok-Ki Choi, Paul R. Fatheree, Robert Murray McKinnell, Brooke Olson
-
Patent number: 8653124Abstract: Disclosure is provided for imidazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same.Type: GrantFiled: February 2, 2011Date of Patent: February 18, 2014Assignee: North Carolina State UniversityInventors: Christian Melander, John Cavanagh, Robert W. Huigens, III, T. Eric Ballard, Justin J. Richards
-
Publication number: 20140045796Abstract: The identification of pO2 lowering agents as transient hypoxia-inducers is disclosed herein. Provided is a method of enhancing the efficacy of a hypoxia-sensitive agent in a subject, by administering to the subject a therapeutically effective amount of the hypoxia-sensitive agent and a therapeutically effective amount of a pO2 lowering agent. Methods of treating a subject with a tumor, by administering to the subject a therapeutically effective amount of a pO2 lowering agent and a therapeutically effective amount of a hypoxia-sensitive agent are also disclosed.Type: ApplicationFiled: April 20, 2012Publication date: February 13, 2014Applicants: H.Lee Moffitt Cancer Center and Research Institute, Inc., Human ServicesInventors: Shingo Matsumoto, Robert J. Gillies, James B. Mitchell, Murali K. Cherukuri, Keita Saito
-
Publication number: 20140031331Abstract: The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.Type: ApplicationFiled: September 19, 2013Publication date: January 30, 2014Inventors: Wilhelm Amberg, Michael Ochse, Udo Lange, Andreas Kling, Berthold Behl, Wilfried Hornberger, Mario Mezler, Charles W. Hutchins
-
Patent number: 8637058Abstract: Composition for controlling phytopathogens comprising compound of the formula: wherein: R1 represents H, or a CO—R? acyl group; R2, the same or different when n is equal to 2, is a halogen, optionally selected from fluorine, chlorine, bromine or iodine; a C1-C9 alkyl group; a C1-C9 haloalkyl group; a C1-C9 alkoxyl group; a C1-C9 haloalkoxyl group; a C1-C9 thioalkyl group; a C1-C9 halothioalkyl group; a C3-C9 cycloalkyl group; a C2-C10 carboalkoxyl group; a cyano group; a hydroxyl group; R? represents a hydrogen; a C1-C9 alkyl group; a C1-C9 haloalkyl group; a C1-C9 alkoxyl group; a C1-C9 haloalkoxyl group; a C2-C10 carboalkoxyl group; a phenyl group; n is a number ranging from 0 to 2; X represents an oxygen atom, a nitrogen or sulfur atom in combination with a fungicide; method for controlling phytopathogens with compound of formula (1) with or without another fungicide.Type: GrantFiled: November 18, 2002Date of Patent: January 28, 2014Assignee: Isagro S.p.A.Inventors: Lucio Filippini, Marilena Gusmeroli, Alexia Elmini, Carlo Garavaglia, Luigi Mirenna
-
Patent number: 8637562Abstract: The invention relates to methods for detecting the presence of a compound of formula I in a biological test sample: where R2, R3, and R4 are as defined in the specification; or a salt thereof.Type: GrantFiled: December 17, 2012Date of Patent: January 28, 2014Assignee: Theravance, Inc.Inventors: Yuqin Dai, Donavon McConn, Huiyu Zhou
-
Patent number: 8637561Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: February 17, 2010Date of Patent: January 28, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yao-Ling Qiu, Lu Ying, Ce Wang, Xiaowen Peng, Yat Sun Or
-
Publication number: 20140023691Abstract: Disclosure is provided for imidazole derivative compounds useful to inhibit the formation of biofilms and/or inhibit microbial growth, compositions including these compounds, devices including these compounds, and methods of using the same.Type: ApplicationFiled: September 24, 2013Publication date: January 23, 2014Applicant: North Carolina State UniversityInventors: Christian Melander, W. Steve McCall, Zhaoming Su, Roberta Worthington
-
Publication number: 20140018330Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.Type: ApplicationFiled: July 9, 2013Publication date: January 16, 2014Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Patent number: 8617581Abstract: The present invention relates to compositions for controlling plant pests, which contain the compound of the formula (I) in a mixture with fungicidally active compounds, except for cyclopropylcarboxamide derivatives and azolylmethylcycloalkanes.Type: GrantFiled: June 14, 2010Date of Patent: December 31, 2013Assignee: Bayer Intellectual Property GmbHInventors: Christoph Erdelen, Wolfram Andersch, Klaus Stenzel, Astrid Mauler-Machnik, Wolfgang Krämer
-
Publication number: 20130331413Abstract: Disclosed are compositions and methods for treating and/or preventing infections in mammals, by administering to a mammal a therapeutically effective amount of at least one defensin-like molecule, e.g., in a composition that includes such molecule. Also disclosed are kits that include such molecules, or compositions that include such molecules, as well as instructions for using such molecules to treat a mammal.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventors: Erik DE LEEUW, Alexander D. MACKERELL, JR.
-
Patent number: 8598078Abstract: Compounds of Formula I wherein the substituents are as defined in Claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.Type: GrantFiled: August 21, 2008Date of Patent: December 3, 2013Assignee: Syngenta Crop Protection, LLCInventors: Olivier Loiseleur, Roger Graham Hall, André Denis Stoller, Gerald Wayne Craig, André Jeanguenat, Andrew Edmunds
-
Publication number: 20130317001Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC.Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
-
Publication number: 20130317000Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INCInventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
-
Patent number: 8586010Abstract: The methods described herein provide treatment of rosacea using topical formulations of dapsone. The methods also provide treatment of rosacea with topical dapsone in combination with other active agents, including metronidazole. The methods avoid negative hematologic side effects, including hemolysis and hemolytic anemia, that are associated with oral administration of dapsone.Type: GrantFiled: February 27, 2008Date of Patent: November 19, 2013Assignee: Allergan, Inc.Inventor: John S. Garrett
-
Publication number: 20130303473Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.Type: ApplicationFiled: November 10, 2011Publication date: November 14, 2013Applicant: NOVALIQ GmbHInventor: Clive G. Wilson
-
Publication number: 20130302417Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: July 16, 2013Publication date: November 14, 2013Inventors: Bret Berner, Sui Yuen Eddie Hou
-
Publication number: 20130303505Abstract: TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.Type: ApplicationFiled: August 11, 2010Publication date: November 14, 2013Inventors: Venkataiah Bollu, Brant Clayton Boren, Jackaline Dalgard Julien, Brenton T. Flatt, Nadia Haq, Sarah Hudson, Raju Mohan, Michael Morrissey, Benjamin Pratt
-
Patent number: 8580288Abstract: The present invention provides a composition in which a fungicidal effect against a cultivated crop infected by a plant pathogen is stable and highly active. An excellent agricultural or horticultural fungicide composition for controlling a plant pathogen is provided by using (a) at least one imidazole compound represented by formula (I): wherein R represents a C1-6 alkyl group or a C1-6 alkoxy group; and n represents an integer of 1 to 5 and (b) folpet as active ingredients; by combination as compared to a single use of each compound, and a plant pathogen is thereby controlled.Type: GrantFiled: July 6, 2010Date of Patent: November 12, 2013Assignee: Ishihara Sangyo Kaisha, LtdInventor: Koji Sugimoto
-
Publication number: 20130296393Abstract: In order to control the clubroot of brassica vegetables which is settled-planted in a farm field, it is necessary to previously treat the seedling with a chemical before settled planting or treat the soil with a chemical, but the clubroot is sometimes not controlled depending on the weather or soil conditions. In addition, the treatment with a fungicidal compound at a high concentration causes a problem of phytotoxicity or crop persistence. An object of the present invention is to solve these problems and provide a method for easily and simply controlling clubroot without causing a problem of phytotoxicity or crop persistence. The present invention provides a method for controlling clubroot, comprising applying cyazofamid to brassica vegetables after seeding or settled planting in a farm field.Type: ApplicationFiled: January 11, 2012Publication date: November 7, 2013Applicant: ISHIHARA SANGYO KAISHA, LTD.Inventors: Hiroyuki Hayashi, Masanari Ohno
-
Publication number: 20130295025Abstract: The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.Type: ApplicationFiled: January 9, 2012Publication date: November 7, 2013Applicant: INVION LIMITEDInventors: Richard A. Bond, Mitchell Glass
-
Publication number: 20130274305Abstract: The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art. The present invention relates to novel nitroimidazole derivates represented by formula (1).Type: ApplicationFiled: December 21, 2011Publication date: October 17, 2013Applicants: STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC", CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Philippe Lambin, Jean-Yves Winum, Claudiu Supuran
-
Publication number: 20130267486Abstract: The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need thereof, and to the use of such compositions in the treatment of bacterial conditions.Type: ApplicationFiled: June 5, 2013Publication date: October 10, 2013Inventor: Prashant SAWANT
-
Publication number: 20130267573Abstract: The invention provides crystalline salt forms of 4?-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]-imidazol-1-ylmethyl}-3?-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compounds, processes and intermediates for preparing the crystalline compounds, and methods of using the crystalline compounds to treat diseases such as hypertension.Type: ApplicationFiled: December 19, 2012Publication date: October 10, 2013Applicant: THERAVANCE, INC.Inventor: Paul R. Fatheree
-
Patent number: 8552048Abstract: Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases.Type: GrantFiled: December 21, 2007Date of Patent: October 8, 2013Assignee: Threshold Pharmaceuticals, Inc.Inventors: Steve Ammons, Jian-Xin Duan, Donald Jung, Mark Matteucci
-
Publication number: 20130259947Abstract: The present invention relates to an oral pharmaceutical composition comprising metronidazole, wherein metronidazole is released from the composition generally at the pH 5.0 and above.Type: ApplicationFiled: November 29, 2011Publication date: October 3, 2013Applicant: DR. REDDY'S LABORATORIES LTD.Inventors: Bijay Kumar Padhi, Muzammil Tariq, Sagar Dilip Mandawgade, Rajesh Gandhi, Rajeev Singh Raghuvanshi, Dushyanth Surakanti, Kent Allenby
-
Publication number: 20130261572Abstract: Disclosed is a patch which is a formulation including deposited clonidine crystals and provides stable transdermal absorbability even after storage at varying temperatures. The patch disclosed includes a backing and a medicated layer integrally superposed on one surface of the backing. The medicated layer contains: 5 to 30% by weight of clonidine including clonidine in a crystallized state; 25 to 90% by weight of a macromolecular base (A) having a viscosity-average molecular weight of 800,000 or larger; and 5 to 60% by weight of a liquid additive capable of dissolving the clonidine. The weight ratio of the liquid additive to the macromolecular base (A) [the liquid additive/the macromolecular base (A)] is 0.1 to 2.0.Type: ApplicationFiled: November 2, 2011Publication date: October 3, 2013Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroko Udagawa, Yoshikazu Inaba, Yukihiko Noda, Kumi Obata, Hiroto Terashima
-
Patent number: 8541459Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.Type: GrantFiled: January 17, 2008Date of Patent: September 24, 2013Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Publication number: 20130244962Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.Type: ApplicationFiled: April 11, 2013Publication date: September 19, 2013Applicant: Merck Frosst Canada Ltd.Inventors: Elise ISABEL, Christopher MELLON, Christian BEAULIEU
-
Publication number: 20130244985Abstract: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.Type: ApplicationFiled: May 10, 2013Publication date: September 19, 2013Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20130243837Abstract: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an ?2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours.Type: ApplicationFiled: April 15, 2013Publication date: September 19, 2013Applicant: Galderma Laboratories Inc.Inventors: Jack DeJovin, Isabelle Jean DeJovin
-
Publication number: 20130237573Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.Type: ApplicationFiled: November 15, 2011Publication date: September 12, 2013Applicant: ELI LILLY AND COMPANYInventors: Bruce Anthony Dressman, Mark Donald Chappell, Adam Michael Fivush, Charles Howard Mitch, Paul Leslie Ornstein, Eric George Tromiczak, Tatiana Natali Vetman
-
Patent number: 8530507Abstract: The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole, and anti-anaerobic activities which are slightly better than or substantially the same as that of the racemic ornidazole. Also, this invention particularly relates to a preparation process, which comprises formulating L-ornidazole as anti-anaerobic infection pharmaceutical preparations, which are suitable for clinical uses.Type: GrantFiled: April 17, 2006Date of Patent: September 10, 2013Assignee: Nanjing Sanhome Pharmaceutical Co., Ltd.Inventors: Yong Wang, Cang Zhang, Zaijin Teng, Li Li
-
Publication number: 20130230588Abstract: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract.Type: ApplicationFiled: April 15, 2013Publication date: September 5, 2013Applicant: TEMREL LIMITEDInventors: Christopher J. SPEIRS, Peter MOIR, Richard WILLIAMS, Michael CLARK
-
Publication number: 20130225621Abstract: In one aspect, the invention relates to substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs, derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: August 2, 2011Publication date: August 29, 2013Applicants: University of Toronto Mississauga, University of Central Florida Research Foundation, Inc.Inventors: James Turkson, Patrick Gunning
-
Publication number: 20130225587Abstract: The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders.Type: ApplicationFiled: November 9, 2011Publication date: August 29, 2013Applicants: Zhejiang Beta Pharma Incorporation, Fujian Haixi Pharmaceuticals, Inc.Inventors: Xinshan Kang, Wei Long, Cunbo Ma, Yanping Wang, Xiaoyan Shen, Yunyan Hu, Fenlai Tan, Yinxiang Wang
-
Publication number: 20130217741Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.Type: ApplicationFiled: March 15, 2013Publication date: August 22, 2013Applicant: S.L.A. PHARMA AGInventor: S.L.A. PHARMA AG
-
Publication number: 20130217742Abstract: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.Type: ApplicationFiled: April 2, 2013Publication date: August 22, 2013Applicant: Dow Pharmaceutical Sciences, Inc.Inventor: Dow Pharmaceutical Sciences, Inc.
-
Publication number: 20130217740Abstract: A compound of formula (I): is described, as well as enantiomers, pharmaceutically acceptable salts thereof, and uses thereof.Type: ApplicationFiled: June 29, 2011Publication date: August 22, 2013Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Jean-Guy Boiteau, Jean-Michel Linget
-
Publication number: 20130210837Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: ASTRAZENECA INTELLECTUAL PROPERTYInventors: Gabor Csjernyik, Sofia Karlstrom, Annika Kers, Karin Kolmodin, Martin Nylof, Liselotte Ohberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Soderman, Britt-Marie Swahn, Stefan Von Berg
-
Publication number: 20130202698Abstract: This invention relates to new methods of treating parasitic infections, such as trichomonas vaginalis infection and cecum amoeba infection, using L-enantiomer enriched ornidazole, in particular enantiomerically pure L-ornidazole, which provides benefits such as higher efficacy and lower toxicity to central nervous system over the existing racemic Ornidazole drug. New methods of synthesizing L- and D-enantiomers of Ornidazole in high purity and enantiomeric excess (ee), new formulations of the enantiomerically enriched L- or D-ornidazole, as well as their preparation processes and methods of use, are also disclosed.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventor: Nanjing Sanhome Pharmaceutical Co., Ltd.
-
Publication number: 20130197048Abstract: A compound of formula (I): is described, as well as pharmaceutically acceptable salts thereof, and its use as a medicament.Type: ApplicationFiled: June 29, 2011Publication date: August 1, 2013Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Jean-Guy Boiteau, Jean-Michel Linget
-
Publication number: 20130195943Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130195944Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Patent number: 8497289Abstract: In one aspect, the invention relates to compounds which are useful as inhibitors of glycine type 1 transporter (GlyT1) activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with glycine type 1 transporter (GlyT1) activity using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 29, 2009Date of Patent: July 30, 2013Assignee: Vanderbilt UniversityInventors: Craig W. Lindsley, P. Jeffrey Conn, Richard Williams, Carrie K. Jones, Douglas J. Sheffler
-
Publication number: 20130190363Abstract: An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient.Type: ApplicationFiled: July 15, 2011Publication date: July 25, 2013Applicants: WAKUNAGA PHARMACEUTICAL CO., LTD., NEUGEN PHARMA INC.Inventors: Joh-E Ikeda, Noriaki Hirayama, Satoshi Inoue, Kazunori Tanaka, Takuya Kanno